Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Georgina V. Long(The University of Sydney), Matteo S. Carlino(The University of Sydney), Anna J. Lomax(The University of Sydney), Alexander Guminski(The University of Sydney), Alexander M. Menzies(The University of Sydney), Bernie Fitzharris(Christchurch Hospital), Jonathan Cebon(La Trobe University), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Babak Tamjid(La Trobe University), Benjamin Y. Kong(Prince of Wales Hospital), Xinxin Shu(Georgetown University), Catriona M. McNeil(Chris O’Brien Lifehouse), Andrew Hill(University of Auckland), Richard Kefford(Broad Institute), Mohammed Rafiqul Islam(Trans Tasman Radiation Oncology Group), Antoni Ribas(University of California, Los Angeles), F. Stephen Hodi(Harvard University), John A. Thompson(Fred Hutch Cancer Center), Archana Srivastava(Jewish General Hospital), Michael B. Atkins(Georgetown Lombardi Comprehensive Cancer Center), Michael B. Jameson(Waikato Hospital), Victoria Atkinson(Greenslopes Private Hospital), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))

The Lancet Oncology

July 17, 2017

Cited by 247

|New England Journal of Medicine|2012|12.6k

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.9k

|New England Journal of Medicine|2014|5.3k

Related Papers